Abstract: Objective To analyze the clinical application value of MR-TRUS image artificial intelligence (AI) fusion-assisted prostate biopsy in prostate cancer screening.Methods This study enrolled 212 prostate cancer patients undergoing prostate biopsy at our hospital from January 2023 to May 2025.They were randomly divided into a fusion group (106 cases,using Venus ultrasound with MR-TRUS image AI fusion guidance) and a traditional group (106 cases,using conventional transrectal ultrasound (TRUS) guidance).The following parameters were compared between the two groups:biopsy positive rate,false-negative rate,detection rate of tumors with different Gleason scores (GS),number of biopsy cores,targeting error,and incidence of postoperative complications (rectal bleeding,urinary tract infection,urinary retention).Results The biopsy positive rate of fusion group was 62.26% (66/106),significantly higher than 43.40% (46/106) in the traditional group (P<0.01).The false-negative rate in the fusion group was 1.89% (2/106),significantly lower than 9.43% (10/106) the traditional group (P<0.01).In the fusion group,the detection rates for tumors with GS≤6、GS=7and GS≥8 26.42％、29.24％and 6.60％，respectively．In the traditional group，these rates were 18.87％、16.98％and 7.55％，respectively.The difference in detection rate for low-to-intermediate-risk differentiated adenocarcinoma was statistically significant (P<0.01).The fusion group had a lower average number of biopsy cores (7.9±1.2) compared to the traditional group (13.2±1.6) (P<0.05) and a smaller targeting error [(1.1±0.3)mm VS (4.0±0.8)mm](P<0.05).The total incidence of postoperative complications in the fusion group was 5.66% (6/106),lower than the 19.81% (21/106) in the traditional group (P<0.05).Conclusion MR-TRUS image AI fusion can improve the detection rate of low-to-intermediate-risk differentiated prostate cancer,reduce the prostate cancer missed diagnosis rate,and decrease biopsy-related trauma and complications.

Key words: prostate cancer, MR-TRUS image fusion, artificial intelligence, aspiration biopsy